California Business

Juno Therapeutics and Celgene Corporation Release Additional Data from TRANSCEND Trial of JCAR017 in Patients with Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma

11 12 2017

SEATTLE & SUMMIT, N.J.--(BUSINESS WIRE)--Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, and Celgene Corporation (NASDAQ: CELG) today released additional data from the TRANSCEND study of JCAR017 (lisocabtagene maraleucel; liso-cel) in patients with relapsed or refractory (r/r) aggressive B-cell non-Hodgkin lymphoma (NHL) in a presentation at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition. “We are highly encouraged by the latest efficacy and tolerability data, particularly at dose level two, as these are patients with a poor prognosis who need better treatment options,” said Sunil Agarwal, M.D., Juno’s President of Research and Development. “These data support a potential best-in-class profile and further support the importance of a defined cell product. We continue to enroll our pivotal cohort in DLBCL patients and over the next twelve to eighteen months...

Quotidian Technical Highlights on Selected Healthcare Stocks -- Quidel, PetMed Express, Valeant Pharma, and Aradigm

11 12 2017

...

This Morning's Technical Outlook on REIT Stocks -- Cousins Properties, Vornado Realty Trust, American Tower, and Colony NorthStar

11 12 2017

...

ApolloMed And Network Medical Management Announce Completion Of Merger And Listing On The Nasdaq Capital Market

11 12 2017

GLENDALE, Calif., Dec. 11, 2017 -- Apollo Medical Holdings, Inc. ("ApolloMed" or "the Company") (NASDAQ: AMEH), an integrated population health management company, and Network Medical Management, Inc. ("NMM"), one of the largest Management Services Organizations ("MSOs") in the United States, today announced the successful completion of their merger.  The newly combined company, which will continue as Apollo Medical Holdings, brings together two leading, complementary healthcare organizations to form one of the nation's largest population health management companies, and will coordinate the care and provide medical management for over 700,000 patients in California through a network of over 4000 contracted physicians and over 400 employees.  Additionally, ApolloMed's shares of common stock were approved for listing on The Nasdaq Capital Market ("NASDAQ").  The Company's common stock began trading on NASDAQ on December 8, 2017 under the ticker symbol "AMEH". ...

Alginate Market Size Worth $923.8 Million by 2025 | CAGR: 4.5%: Grand View Research, Inc.

11 12 2017

...

Standard Lithium Provides Development Update on California Lithium Project

11 12 2017

VANCOUVER, British Columbia, Dec. 11, 2017 -- Standard Lithium Ltd. (“Standard Lithium” or the “Company”) (TSX-V:SLL) (FRA:S5L) (OTCQX:STLHF) is pleased to provide an update on the development work taking place at the Company’s California Lithium Project; comprising the Bristol Dry Lake and the Cadiz Dry Lake lithium brine properties located in the Mojave Desert, California.A total of six new separate evaporation ponds have been installed on the Bristol Dry Lake Property to further assess the role that short-duration passive solar evaporation may play in processing the lithium brines encountered at the project.  Previous work demonstrated that, owing to extremely high evaporation rates in the project area, it is possible to concentrate brines from initial lithium concentrations of 146 mg/L to concentrations of 686 mg/L in approximately 7 weeks (note, this average lithium concentration was previously reported as 556 mg/L in news release dated 10th Oct 2017, but has been revised...

Robert Dillman, MD, Presented with the Albert Nelson Marquis Lifetime Achievement Award by Marquis Who's Who

11 12 2017

    IRVINE, CA, December 11, 2017 -- Marquis Who's Who, the world's premier publisher of biographical profiles, is proud to present Robert Dillman, MD, with the Albert Nelson Marquis Lifetime Achievement Award. An accomplished listee, Dr. Dillman celebrates many years' experience in his professional network, and has been noted for achievements, leadership qualities, and the credentials and successes he has accrued in his field. As in all Marquis Who's Who biographical volumes, individuals profiled are selected on the basis of current reference value. Factors such as position, noteworthy accomplishments, visibility, and prominence in a field are all taken into account during the selection process.Dr. Dillman is the chief medical officer of AIVITA Biomedical, and as such, is at the forefront of an industry committed to developing groundbreaking cancer treatment technologies. Serving more than 35 years in clinical and educational capacities, he has consistently...

Kite Announces Long-Term Data From Pivotal ZUMA-1 Study of Yescarta™ (Axicabtagene Ciloleucel) in Patients With Refractory Large B-cell Lymphoma

10 12 2017

...

Easily Track Employee Leave with Virtual TimeClock 18

10 12 2017

New Virtual TimeClock software release makes it easy to calculate and limit employee leave awards, simplifies common tasks and adds enhanced security. Clovis, CA, December 10, 2017 -- Today's release of Virtual TimeClock 18 from Redcort Software helps simplify employer compliance with changing labor laws regarding worker leave. With over two dozen program enhancements, Virtual TimeClock 18 remains easy-to use while providing organizations with powerful new tools to manage their employee time and attendance.Easily Calculate Leave AwardsThe Affordable Care Act (ACA) and recent changes to labor laws in states like California have created compliance burdens for many employers. "Our most frequent feature request this past year has been to enhance our leave calculator with an annual limit on calculated awards," explained Adam Carmichael, a Product Specialist at Redcort Software. "Virtual TimeClock 18 solves this important business need with simple rules-based settings that impose a cap...

BioMarin Provides 1.5 years of Clinical Data for Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A at 59th American Society of Hematology (ASH) Annual Meeting Concurrent with NEJM Publication

09 12 2017

...

Live Traffic in Fresno, CA